Octagon Capital Advisors LP 13D and 13G filings for Xilio Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-06 4:04 pm Sale | 2024-01-02 | 13G | Xilio Therapeutics, Inc. XLO | Octagon Capital Advisors LP | 0 0.000% | -1,785,000 (Position Closed) | Filing |
| 2024-02-05 4:01 pm Sale | 2023-12-31 | 13G | Xilio Therapeutics, Inc. XLO | Octagon Capital Advisors LP | 1,785,000 6.480% | -640,000 (-26.39%) | Filing |
| 2023-01-25 4:01 pm Purchase | 2022-12-31 | 13G | Xilio Therapeutics, Inc. XLO | Octagon Capital Advisors LP | 2,425,000 8.830% | 2,425,000 (New Position) | Filing |